1Stokes ME, Thompson D, Montoya EL, et al.Ten-Year Survival and CostFollowing Breast Cancer Recurrence: Estimates from SEER-Medicare Data[J]. Value in Health, 2011, 11 ( 2 ) : 213-220.
2Wugk, ZHAO ry.Disussion on the status of dhagnosis,treatment of bre, a,+t cancer andReform Men.sures[J]Joumal of Po.stgraduates of Medicine,2012,23 ( 11 ) : 59-60.
3Miguel M, Tadeusz P, John M, et al.Adjuvant Docetaxel for Node-PositiveBreast Caneer[J].N ENGL J MED,2011,145 ( 5 ) : 2302-2313.
4AU HJ, Golmohammadi K, Younis T, et al.Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects[J].Breast Cancer Res Treat, 2012, 114 ( 3 ) : 579-587.
5Wolowacz SE, Cameron DA, Tate HC, et al.Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node- positive breast cancer: a cost-effectiveness and cost-utility analysis[J].J Clin Oncol,2011,26 ( 6 ): 925-933.
